Star Pharmaceutical delists from Mainboard

The company is going private.

Star Pharmaceutical’s public float fell to 7.75%, less than the minimum Mainboard requirement of 10%, according to an SGX filing.

As of 5pm on Monday, the total number of shares and acceptances owned and controlled by the company and its concert parties reached 42.3 million or approximately 92.25% of shares.

As the pharmaceutical firm no longer holds the minimum free float requirement of the Mainboard, SGX shall close the trading of shares at the close of the offer.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia